$34.00
0.89% yesterday
Nasdaq, Feb 04, 10:00 pm CET
ISIN
US78349D1072
Symbol
RXST

RxSight Inc Stock price

$34.00
-1.40 3.95% 1M
-6.78 16.63% 6M
-0.38 1.11% YTD
-12.70 27.19% 1Y
+23.23 215.69% 3Y
+18.00 112.50% 5Y
+18.00 112.50% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.30 0.89%
ISIN
US78349D1072
Symbol
RXST
Sector

Key metrics

Market capitalization $1.37b
Enterprise Value $1.14b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.92
P/S ratio (TTM) P/S ratio 10.68
P/B ratio (TTM) P/B ratio 4.94
Revenue growth (TTM) Revenue growth 67.51%
Revenue (TTM) Revenue $128.29m
EBIT (operating result TTM) EBIT $-39.08m
Free Cash Flow (TTM) Free Cash Flow $-28.76m
Cash position $237.12m
EPS (TTM) EPS $-0.82
P/E forward negative
P/S forward 9.79
EV/Sales forward 8.17
Short interest 5.93%
Show more

Is RxSight Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

RxSight Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a RxSight Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a RxSight Inc forecast:

Buy
80%
Hold
20%

Financial data from RxSight Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
128 128
68% 68%
100%
- Direct Costs 40 40
22% 22%
32%
88 88
102% 102%
68%
- Selling and Administrative Expenses 90 90
38% 38%
70%
- Research and Development Expense 33 33
14% 14%
25%
-35 -35
30% 30%
-27%
- Depreciation and Amortization 4.19 4.19
2% 2%
3%
EBIT (Operating Income) EBIT -39 -39
28% 28%
-30%
Net Profit -31 -31
44% 44%
-24%

In millions USD.

Don't miss a Thing! We will send you all news about RxSight Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RxSight Inc Stock News

Neutral
GlobeNewsWire
24 days ago
ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance.
Neutral
GlobeNewsWire
about one month ago
ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.
Positive
Seeking Alpha
2 months ago
RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, representing an 80% YoY increase in volume compared to the same period last year. The company's healthy balance sheet supports continued efforts in driving adoption within the U.S. market, while also m...
More RxSight Inc News

Company Profile

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery The company was founded by Robert Grubbs and Daniel Schwartz on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Head office United States
CEO Ronald Kurtz
Employees 374
Founded 1997
Website rxsight.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today